Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2

The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.

Business concept illustrations of diversification. Golden eggs in different baskets. Vector diversification business, golden eggs in basket

Beating expectations for the second quarter, Bristol-Myers Squibb Co. touted the stability of its PD-1 inhibitor Opdivo in second-line metastatic non-small cell lung cancer (NSCLC), as well as the diversity of the immuno-oncology franchise overall, especially strong performance of the Opdivo/Yervoy combo in renal cancer.

Bristol reported second quarter sales of about $1.6bn for Opdivo (nivolumab) on July 26, up by 36% year-over-year, helping to...

More from Earnings

More from Business